



**Dicerna to Report Third Quarter 2017 Financial Results and
Host Conference Call on November 2, 2017**

CAMBRIDGE, Mass., October 26, 2017 -- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2017 financial results after market close on Thursday, November 2, 2017.

Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the Internet and will be available on the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website.

The call can also be accessed by dialing (855) 453-3834 or (484) 756-4306 (international), and referencing conference ID 95620574 prior to the start of the call. After the conference call, a replay will be available until November 9, 2017. To access the replay, please dial (855) 859-2056 or (404) 537-3406, and refer to conference ID 95620574.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Investor Contact:

Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

Media Contact:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com